Searchable abstracts of presentations at key conferences in endocrinology

ea0016p365 | Growth factors | ECE2008

Association between serum levels of insulin-like growth factor-I and development of congestive heart failure: a prospective study in a normal population

Andreassen Mikkel , Raymond Ilan , Kistorp Caroline , Hildebrandt Per , Faber Jens

Background: The growth hormone system (growth hormone, GH and insulin-like-growth-factor I, IGF-I) might be implicated in congestive heart failure (CHF). In experimental models IGF-I increases cardiac contractility and reduces apoptosis of myocytes exposed to ischemic injury. In clinical studies GH-therapy has been used in CHF. One previous population based investigation showed that low levels of IGF-I was associated with an increased incidence of CHF. The result of this inves...

ea0014p371 | (1) | ECE2007

Increased risk of cardiovascular events in subclinical hyperthyroidism

Schultz Marianne , Kistorp Caroline , Raymond Ilan , Faber Jens

Objective: Untreated overt hyperthyroidism is known to predispose the patient to cardiovascular diseases, while predisposition in subclinical hyperthyroidism has been debated. The1 cut-off point of TSH for initiating treatment in subclinical hyperthyroidism is still undefined.Method: A community-based prospective study including non-hospitalised participants, aged 51 to 91 years, living in Copenhagen, Denmark were examined between September 1998 and Janu...

ea0035oc1.3 | Thyroid clinical | ECE2014

Chronic liothyronine (T3) treatment in stable heart failure patients with low T3 syndrome: A randomised, double-blind, cross-over, placebo-controlled intervention study (The LIHFA study)

Holmager Pernille , Schmidt Ulla , Dall Mark Peter , Dominguez Helena , Zerahn Bo , Raymond Ilan , Kistorp Caroline , Nygaard Birte , Faber Jens

Background and aim: Low T3 syndrome is associated with a poor prognosis in patients with chronic heart failure (CHF). It is controversial whether T3 treatment is indicated in CHF. A previous study using intravenous infusion of T3 for 72 h suggested a beneficial effect on cardiac performance.We aimed to evaluate the effect of 13 weeks of T3 treatment in patients with stable CHF on left ventricular ejection fraction (LVEF) compared to placebo.<p class=...